Medipost Participates in Bio Asia-Taiwan 2025

Full-Scale Expansion into the APAC Market

Medipost announced on the 29th that it participated in "Bio Asia-Taiwan 2025," which was held in Taipei, Taiwan from July 23 to July 27.

A Medipost representative is presenting the company introduction at 'Bio Asia-Taiwan 2025,' held in Taipei, Taiwan, from the 23rd to the 27th. Medipost

"Bio Asia-Taiwan 2025" is the largest annual biotechnology event in the Asia-Pacific (APAC) region. As of last year, the large-scale international conference attracted over 2,200 participants from 56 countries and hosted more than 8,200 partnering meetings.

Through its participation in this conference, Medipost actively promoted its capabilities as a total solution provider in the field of cord blood stem cells, marking the official start of its expansion into the Asian market. In particular, the company delivered a corporate presentation highlighting its integrated solution capabilities across all areas, including stem cell therapy development and domestic commercialization achievements, global clinical development of Cartistem, and contract development and manufacturing (CDMO) business.

Regarding Cartistem's domestic performance since its launch in 2012, Medipost also introduced a real-world evidence (RWE) study currently being conducted at 12 institutions in Korea. This study is collecting long-term data on 500 Cartistem-treated patients to assess long-term safety and efficacy, including rates of switching to other treatments or surgery, the quality and composition of regenerated cartilage, and adverse events.

The company also sought to establish strategic partnerships that would enable market entry within the Asia-Pacific region. The ongoing phase 3 clinical trial of Cartistem in Japan is scheduled for completion in the second half of this year. Accordingly, Medipost plans to apply for product approval in Japan in the second half of 2026, with the goal of obtaining approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in the second half of 2027. Based on this, the company intends to actively strengthen partnerships from this year through next year, focusing on APAC countries where product approval applications are possible without additional clinical trials.

Medipost also carried out systematic partnering activities to expand global partnerships within the APAC region. The company focused on identifying potential partners in the field of cord blood stem cell therapies, as well as deepening networking and conducting strategic face-to-face meetings with existing collaborators.

In particular, leveraging the successful clinical trials and long-term follow-up results in Korea, regulatory approval from the Ministry of Food and Drug Safety, and extensive data accumulated through actual commercialization, Medipost presented concrete and feasible collaboration plans for entering local markets in various APAC countries. Through this, the company actively sought opportunities for various forms of strategic alliances, including licensing, joint clinical development, and local manufacturing partnerships. Going forward, Medipost plans to conduct a comprehensive analysis of regulatory policies for stem cell therapies, market accessibility, and the willingness of local medical professionals to adopt such therapies in each APAC country, in order to develop tailored market entry strategies for each market.

A Medipost representative stated, "Through our participation in Bio Asia-Taiwan 2025, we will actively showcase our differentiated capabilities in the field of stem cells to the Asian market and expand our strategic partnerships within the APAC region. In particular, based on our successful commercialization experience in Korea and global clinical data, we aim to establish a new breakthrough for entry into various Asian countries."